Drug Profile


Latest Information Update: 21 Jan 2015

Price : $50

At a glance

  • Originator Gideon Pharmaceuticals
  • Developer Elorac
  • Class Antiallergics; Dibenzoxepins; Oxepins; Skin disorder therapies; Small molecules; Xanthenes
  • Mechanism of Action Adrenergic uptake inhibitors; Histamine H1 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic rhinitis; Urticaria
  • Discontinued Atopic dermatitis; Contact dermatitis

Most Recent Events

  • 14 Jan 2015 Phase-II clinical trials in Allergic rhinitis in USA (PO)
  • 14 Jan 2015 Phase-II clinical trials in Urticaria in USA (PO)
  • 19 Oct 2010 Investigation in Contact dermatitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top